Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?

Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs which target specific mutations such as EGFR and ALK have been at the forefront and this has been further supplemented with the application of anti-PD-1/PD-L1 agents (as monotherapies or in combination) where Merck’s Keytruda® (Pembrolizumab) has been leading the charge. In fact, ASCO 2018 has solidified Merck’s dominant position in first line settings.